Alecensa 150 MG capsule UU 240S
Ended Awarded Last action
- Contract number
- SPE2DR26FHNV7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $28,029
Award facts
- Contract value 100% obligated
- $28,028.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $28,028.92 to DMS Pharmaceutical Group Inc. on January 28, 2026, for the supply of Alecensa 150 mg capsules (240-count units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected under a firm fixed-price delivery order with an ultimate completion date of February 19, 2026. No set-aside designation was applied to this award, indicating the contractor competed in an unrestricted procurement environment. The contract type and pricing structure reflect the Defense Logistics Agency's standard approach for pharmaceutical procurement through established vendor relationships.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to ensure comprehensive pharmaceutical supply to Department of Defense military healthcare facilities worldwide. DMS Pharmaceutical Group holds a single-award IDC designated as contract SPE2DR, valued at $499,999,999 through December 31, 2036, positioning the company as one of multiple regional prime vendor contractors. The PPV-G GEN V program authorizes the Defense Logistics Agency to issue firm fixed-price delivery orders for branded and generic prescription drugs, biologics, and medical consumables to support recurring medical supply requirements across the military healthcare system globally.
Quick answers
Who was awarded contract SPE2DR26FHNV7?
SPE2DR26FHNV7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FHNV7 worth?
The government has obligated $28,029 on SPE2DR26FHNV7.
Is contract SPE2DR26FHNV7 an order under another contract?
Yes. SPE2DR26FHNV7 is a delivery order under SPE2DR25D9231, an indefinite delivery contract.
Was contract SPE2DR26FHNV7 competed?
The extent of competition for SPE2DR26FHNV7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award